Water Utilities Set the Pace in Race to Reduce Carbon Emissions
11.10.2022 16:00:00 EEST | Business Wire | Press release
More than 80 water and wastewater utilities worldwide have set net-zero and climate-neutrality targets.1 These utilities are leading the decarbonization of the water sector with strategies that optimize operations while cutting greenhouse gas (GHG) emissions. A new paper from global water technology company Xylem (NYSE: XYL), Net Zero: The Race We All Win , shows how water managers are reducing their emissions and making infrastructure more resilient to climate change.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221011005083/en/
Learn about some of the strategies that are helping utilities reduce emissions in Xylem's new paper. (Graphic: Business Wire)
“We have an opportunity to help the water sector be the fastest to reduce its carbon emission footprint. Utilities, already on the frontlines of the effects of climate change and aging infrastructure, and passionate public servants, are the key,” said Patrick Decker, President and CEO of Xylem. “This paper and action show how leading water utility managers are delivering real progress toward net-zero goals. And these examples show how quickly and affordably they are doing it, while optimizing their overall operations. The technology exists to address these challenges, and the time to make a difference is now.”
Water infrastructure accounts for approximately 2% of global GHG emissions – the same as the global shipping industry. Net Zero: The Race We All Win, which is available to download , highlights pragmatic approaches and proven technologies that can reduce water utility emissions to net zero. The methods used by pace-setting utilities include:
- Create a smart net zero strategy – realistic, measurable targets towards emissions-reduction goals
- Optimize energy and resources across a network – cost-neutral strategies to reduce emissions while ensuring process stability
- Embed net-zero goals in capital planning – net-zero criteria that fold into existing processes and the flow of day-to-day decision-making
- Move from treatment to resource recovery – from wastewater as a by-product to be managed to a resource
Among the success stories highlighted in the paper is the City of South Bend, Indiana. The city used technology to reduce combined sewer overflow volume by more than 70 percent. This prevented needless construction of new grey infrastructure and eliminated the associated embedded carbon. The city improved system performance and capacity utilization, and delivered environmental gains 10 to 15 years ahead of schedule.
“While the headline figure of our work was that the city has saved approximately $500 million in capital work savings, the impact on our carbon footprint should not be overlooked. By avoiding a large construction project and prolonging the life or our infrastructure through smart technology, we have made a major impact in reducing our carbon footprint,” said Kieran Fahey, Director, Long-Term Control Plan at the Department of Public Works, City of South Bend.
In another example, EWE WASSER GmbH (EWE) in Cuxhaven, one of Germany’s largest wastewater companies, reduced energy use by 30 percent in part of its operations. Its plant has the capacity to treat wastewater for 400,000 people, and the reductions saved 1.1 million kWh annually, enough energy to power 275 homes for one year, while ensuring high water quality.
Xylem executives will be leading decarbonization conversations at WEFTEC 2022 and European Energy Efficiency Day this week, and at the COP27 climate change conference in Egypt next month.
Xylem was named “Net Zero Carbon Champion” at the 2022 Global Water Awards. This award recognized the Company’s work to accelerate the decarbonization of the water sector and its pledge to partner with utilities, businesses, and water managers around the world to help reduce their carbon footprint. It also acknowledged the Company’s commitments in sustainability: in the last two years the Company has already reduced the CO2 footprint of its water customers by over 1 million metric tons.
About Xylem
Xylem (XYL) is a leading global water technology company committed to solving critical water and infrastructure challenges with innovation. Our 17,000 diverse employees delivered revenue of $5.2 billion in 2021. We are creating a more sustainable world by enabling our customers to optimize water and resource management, and helping communities in more than 150 countries become water-secure. Join us at www.xylem.com.
1 https://www.globalwaterintel.com/water-without-carbon
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221011005083/en/
Contact information
Houston Spencer
+1 (914) 240-3046
Houston.Spencer@xylem.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
